127 results on '"Siegel, David A"'
Search Results
2. A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019
3. Integrating phytoplankton pigment and DNA meta‐barcoding observations to determine phytoplankton composition in the coastal ocean
4. Sampling uncertainties of particle size distributions and derived fluxes
5. Pediatric rhabdomyosarcoma incidence and survival in the United States: An assessment of 5656 cases, 2001–2017
6. Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges
7. Incidence and 5‐year survival of children and adolescents with hepatoblastoma in the United States
8. Sampling uncertainties of particle size distributions and derived fluxes
9. Pembrolizumab, Lenalidomide and Dexamethasone Post Autologous Transplant in Patients with High‐Risk Multiple Myeloma
10. Tissue‐specific differences in HIV DNA levels and mechanisms that govern HIV transcription in blood, gut, genital tract and liver in ART‐treated women
11. Patient‐reported outcomes following autologous stem cell transplant for patients with multiple myeloma
12. Immune tolerance with combined allogeneic haplo‐identical haematopoietic stem cell transplant and renal transplant
13. Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial
14. Use of the prostate‐specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventions
15. Use of theprostate‐specificantigen (PSA) test in the United States for men age ≥65, 1999–2015: Implications for practice interventions
16. Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
17. A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
18. Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma
19. The role of reward sensitivity and childhood maltreatment in predicting nonsuicidal self‐injury
20. Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH
21. Public servants and politics: Developing political acuity in local government
22. Pediatric cancer mortality and survival in the United States, 2001‐2016
23. Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials
24. Evaluation of accuracy and precision in an amplicon sequencing workflow for marine protist communities
25. Seascape genetics of the stalked kelpPterygophora californicaand comparative population genetics in the Santa Barbara Channel
26. Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
27. Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE ‐023 study
28. Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
29. Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013
30. Survival among children diagnosed with acute lymphoblastic leukemia in the United States, by race and age, 2001 to 2009: Findings from the CONCORD-2 study
31. Racial and ethnic differences in survival of pediatric patients with brain and central nervous system cancer in the United States
32. Analyzing Computational Models
33. Recording routine forensic mental health evaluations should be a standard of practice in the 21st century
34. Biphasic Electrical Stimulation Promotes Insulin Release
35. Redox Modulation of NQO1
36. Global surface ocean phytoplankton community structure determined from co-variability in phytoplankton pigment concentrations
37. Satellite sensor requirements for monitoring essential biodiversity variables of coastal ecosystems
38. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
39. Regional patterns of physiological condition determine giant kelp net primary production dynamics
40. Understanding Income Disparities in Infant Feeding Practices: Parent Voices and Practitioner Experiences
41. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
42. Population Pharmacokinetics and Exposure–Response Relationship of Carfilzomib in Patients With Multiple Myeloma
43. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens
44. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay
45. Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series
46. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia
47. Connectivity structures local population dynamics: a long‐term empirical test in a large metapopulation system
48. Seascape drivers ofMacrocystis pyriferapopulation genetic structure in the northeastPacific
49. Modeling fish production for southern California's petroleum platforms
50. The “public service bargain” in local government: A new way of looking at relations between municipal councils and CAOs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.